Clinical trials: Clostridium Difficile (C. Difficile)
Clostridium Difficile Infection
Harnessing the Healthy Gut Microbiota to Cure Patients With Recurrent C. Difficile Infection
CDI (Clostridium difficile infection) causes diarrheal illness and can cause colitis which may be fatal. A patient being treated for CDI has a 10-25% chance of developing relapse. Recurrent CDI is on the rise.
- Trial name
- NCT01372943
- Testing
- "synthetic stool" or pure cultures of probiotic intestinal bacteria
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- Queen's University
Clostridium Difficile Infection
COMBACTE-CDI Understanding the Burden of C. Difficile Infection
Clostridium difficile infection (CDI) is the most common cause of antibiotic associated diarrhoea in the western world. The infection causes significant diarrhoea, which in some cases can be serious and lead to secondary…
- Trial name
- COMBACTE-CDI (NCT03503474)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 3,240 people
- Sponsor
- University of Leeds
Clostridium Difficile Infection
Fecal Microbiota Transplantation for C Diff Infection
The objective of this study is to provide treatment with Fecal Microbiota Transplantation (FMT) to patients with recurrent or refractory Clostridium difficile infection (CDI).
- Trial name
- NCT01905709
- Testing
- Human fecal matter
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Englewood Hospital and Medical Center
Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence
Secondary Prevention of Clostridioides Difficile Using Vancomycin
Re-exposure to systemic antibiotics (i.e., antibiotics absorbed into the bloodstream) is common after a Clostridioides difficile infection (CDI) and is the strongest risk factor for a recurrent episode.
- Conditions
- Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Clostridoides Difficile Associated Disease
- Trial name
- SPORES-V (NCT06979609)
- Testing
- Oral Vancomycin Prophylaxis
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Clostridium Difficile Infection, Hematologic Diseases
Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
This study will randomized hematology oncology patients with active diarrhea and a NAAT positive/toxin EIA negative to either 14 days of oral vancomycin capsules or placebo.
- Conditions
- Clostridium Difficile Infection, Hematologic Diseases, Bone Marrow Transplant, Oncologic Disorders
- Trial name
- NCT03030248
- Testing
- Vancomycin Oral Capsule
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Medical College of Wisconsin
Clostridioides Difficile Infection, Clostridium Difficile Infection
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
This is a randomized, double-blind, placebo-controlled trial to determine the optimal dose and safety of oral alanyl-glutamine between 4, 24, and 44 g doses administered for 10 days with standard therapy among first time incident…
- Conditions
- Clostridioides Difficile Infection, Clostridium Difficile Infection, Clostridium Difficile Diarrhea, Clostridia Difficile Colitis
- Trial name
- ACT (NCT04305769)
- Testing
- Alanyl-glutamine
- Where
- 2 sites in United States
- Volunteers
- 260 people
- Sponsor
- University of Virginia
Clostridium Difficile Infection
Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile
This study proposes to: 1. Characterize the impact of oral vancomycin on C. difficile loads after end of treatment compared to a placebo group. 2.
- Trial name
- NCT03827447
- Testing
- Vancomycin Oral Capsule
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Medical College of Wisconsin
Clostridium Difficile Infection
Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)
The purpose of this study is to determine whether Fecal Microbiota Therapy (FMT) is effective vs. placebo in the prevention of C. difficile infection recurrence.
- Trial name
- MATCH (NCT03005379)
- Testing
- Fecal Microbiota Therapy (FMT)
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- VA Office of Research and Development
Clostridium Difficile Infection
Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum
Fecal microbiota transplantation (FMT) is the reconstitution of normal flora by a "stool transplant" from a healthy individual to a C.
- Trial name
- NCT01704937
- Testing
- Fecal Microbiota Transplant (FMT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Clostridium Difficile Infection
Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics
This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a suspected or confirmed bacterial…
- Trial name
- NCT03466502
- Testing
- Oral Vancomycin
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- University of Nevada, Reno
C. Difficile, C. Difficile Infection
Clostridioides Difficile Controlled Human Infection Model
This study will investigate in healthy study subjects, the safety and tolerability of a controlled infection with Clostridioides difficile, a gut bacterium that can cause diarrhoea.
- Conditions
- C. Difficile, C. Difficile Infection, Controlled Human Infection
- Trial name
- CloDiCHI (NCT06702345)
- Testing
- encapsulated 10^4 CFU toxigenic. C. difficile spores, Vancomycin, Clindamycin
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Clostridium Difficile Infection
Pathogenic Mechanisms in C Diff Infection and Colitis
The purpose of this study is to learn more about infection by Clostridium difficile (also known as C. difficile). C. difficile is a common bacterium (a germ that may cause disease) that can live in the human gut.
- Trial name
- NCT01930032
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Clostridium Difficile
Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.
This study will examine whether the human monoclonal antibody, bezlotoxumab administered AFTER acute Clostridioides difficile (C.diff) has resolved, but during a period of subsequent antibiotic therapy, will eliminate the high…
- Trial name
- NCT03937999
- Testing
- Bezlotoxumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Montefiore Medical Center
Clostridium Difficile Infection Recurrence
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
This trial will be initiated to explore whether RBX2660 (REBYOTA®) could be suitable for administration by the practice of colonoscopy.
- Trial name
- CDI-SCOPE (NCT05831189)
- Testing
- RBX2660
- Where
- 12 sites in United States
- Volunteers
- 41 people
- Sponsor
- Ferring Pharmaceuticals